Joe Ryan Delaney

15PUBLICATIONS
45CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsEpigenetics (incl. genome methylation and epigenomics)Genome structure and regulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 17, 2026
Metallothionein loss in cancer cells contributes to increased mutations through defective DNA repair and metabolic imbalance.

|Aug 11, 2025
PIWIL2 downregulation in colon cancer promotes transposon activity and pro-tumorigenic phenotypes.

Alyssa Risner, Joyce Nair-Menon, Abhinav Cheedipudi

|Jun 26, 2025
Half the Chromosome It Used to Be: Identifying Cancer Treatments Targeting Aneuploid Losses.

Andrew O Disharoon, Joe R Delaney

|Jun 06, 2025
PIWIL2 downregulation in colon cancer promotes transposon activity and pro-tumorigenic phenotypes.

Alyssa Risner, Joyce Nair-Menon, Abhinav Cheedipudi

|Jan 25, 2025
Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer.

Amy Rees, Evan Villamor, Della Evans

|Jan 20, 2025
MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer.

Imade Williams, Matthew O'Malley, Haddie DeHart

Pageof 3

Frequent Collaborators

3 joint publications

David T Long

2 joint publications

Christian M Jones

2 joint publications

Vamsi Gangaraju

2 joint publications

Mirna Mina-Abouda